In VivoAs biosimilars flood into the wet age-related macular degeneration (AMD) market, they are reshaping the competitive landscape that was long dominated by anti-vascular endothelial growth factor (VEGF)
ScripTwo San Francisco Bay-area biotechs – Adverum Biotechnologies, Inc. and 4D Molecular Therapeutics Inc. – presented updated Phase II readouts on 17 July for their gene therapy candidates for wet ag
ScripPreliminary Phase II data in wet age-related macular degeneration (wet AMD) give a leg up to Adverum Biotechnologies, Inc. ’s ixoberogene soroparvovec (ixo-vec), its gene therapy for retinal diseases
ScripThe number of biopharma initial public offerings in the US in 2024 grew to four with IPOs by Alto Neuroscience Inc. and Fractyl Health , showing that investors continue to be supportive of certain